Friday, March 20, 2020

08:15–08:30 Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences
Chair (s): TBA

08:30-08:45 Genetic predisposition
08:45-08:50 Discussion
Jennifer Brown (Boston)

08:50-09:05 Genetic landscape
09:05-09:10 Discussion
Cathy Wu (Boston)

09:10-09:25 Ibrutinib
09:25-09:30 Discussion
Jennifer Woyach (Colombus)

09:30-09:45 Epigenetic landscape
09:45-09:50 Discussion
Chris Oakes (Columbus)

09:50-10:05 Risk stratification: future perspective
(complex karyotype? NOTCH1?)
10:05-10:10 Discussion
Panagiotis Baliakas (Uppsala)

10:10-10:40 Panel discussion

10:40-11:10 Coffee Break

SESSION II – The role of BCR activation and signalling for CLL
Chair (s): TBA

11:10-11:25 BCR isotypes/autonomous signalling
11:25-11:30 Discussion
Hassan Jumaa (Ulm)

11:30-11:45 The latest news on stereotypes
11:45-11:50 Discussion
Kostas Stamatopoulos (Thessaloniki)

11:50-12:05 Novel BCR targets
12:05-12:10 Discussion
Andrew Steele (Southampton)
Next generation BTK inhibitors (covalent/non-covalent?)

Discussion

Short talk

Discussion

Panel discussion

Lunch

Possible slot for a satellite symposium

SESSION III – Therapeutic options for CLL
Chair(s): TBA

15:00-15:15 Ibrutinib for everybody

Jennifer Woyach (Columbus)

15:15-15:20 Discussion

15:20-15:35 Ibrutinib for a small subgroups only

Florence Cymbalista (Paris)

15:35-15:40 Discussion

15:40-15:55 MURANO and MRD

John Seymour (Melbourne)

15:55-16:00 Discussion

16:00-16:15 CLL14 update

Kirsten Fischer (Cologne)

16:15-16:20 Discussion

16:20-16:27 Short talk

TBA

16:27-16:30 Discussion

16:30-17:00 Panel discussion

Coffee break

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)
Chair(s): TBA

17:30-17:45 Ibrutinib trials

Alessandra Tedeschi (Milan)

17:45-17:50 Discussion

17:50-18:05 Ibrutinib real world

George Follows (Cambridge)

18:05-18:10 Discussion

18:10-18:25 Venetoclax trials

Matthew Davids (Boston)

18:25-18:30 Discussion

18:30-18:45 Venetoclax / PI3K real world

Anthony Mato (New York)

18:45-18:50 Discussion

18:50-18:57 Short talk

TBA

18:57-19:00 Discussion

19:00-19:30 Panel discussion

19:30 Get together and poster walks (stand up cocktails and buffet dinner for all)
09:00-10:00  Possible slot for a satellite symposium

09:00-10:00  3 Simultaneous Meet the Expert sessions (non-clinical)

1. Prognostic and predictive markers
   Barbara Eichhorst (Cologne)
2. Resistance to ibrutinib: what to do
   Jennifer Brown (Boston)
3. First line therapy: continuous or time limited treatment?
   Michael Hallek (Cologne)

10:00-10:30  Coffee break

SESSION V – The increasing role of the leukaemic microenvironment
Chair (s): TBA

10:30-10:45  Role of stromal cells
   Andrea Brendolan (Milan)
10:45-10:50  Discussion

10:50-11:05  Tissue recirculation of leukaemic cells
   Silvia Deaglio (Turin)
11:05-11:20  Discussion

11:20-11:35  Role of T cells
   Arnon Kater (Amsterdam)
11:35-11:40  Discussion

11:40-11:55  Immunomodulatory effects of kinase inhibitors
   Adrian Wiestner (Bethesda)
11:55-12:00  Discussion

12:00-12:07  Short talk
   TBA
12:07-12:10  Discussion

12:10-12:40  Panel discussion

12:40-14:30  Lunch

13:20-14:20  Possible slot for a satellite symposium

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL
Chair (s): TBA

14:30-14:45  Next generation PI3K inhibitors
   Peter Hillmen (Leeds)
14:45-14:50  Discussion

14:50-15:05  Novel inhibitors at preclinical level
   Alexey Danilov (Portland)
   (MCL1 & CDK inhibitors)
15:05-15:10  Discussion

15:10-15:25  Optimizing the use of BH3 Mimetics in CLL
   Eric Eldering (Amsterdam)
15:25-15:30  Discussion

15:30-15:45  CAR-T cells
   David Maloney (Seattle)
15:45-15:50  Discussion

15:50-16:05  Allo-transplant
   Peter Dreger (Heidelberg)
16:05-16:10  Discussion
16:10-16:40  

*Panel discussion*

16:40-17:10  

*Coffee break*

**SESSION VII – Efficacy through safety**

Chair (s): TBA

17:10-17:25  

Cardiologist  

Javid Moslehi (Nashville)

17:25-17:30  

*Discussion*

17:30-17:45  

Dermatologist  

Nicole LeBoeuf (Boston)

17:45-17:50  

*Discussion*

17:50-18:05  

Infectious diseases  

Pierluigi Viale (Bologna)

18:05-18:10  

*Discussion*

18:10-18:25  

Gastroenterology  

Stefano Fagiuoli (Bergamo)

18:25-18:30  

*Discussion*

18:30-19:00  

*Panel discussion*

Free evening

**Sunday, March 22, 2020**

07:30-08:30  

3 Simultaneous Breakfast Meet the Expert Sessions (clinical)

1. Treatment of relapsed CLL  

Paolo Ghia (Milan)

2. Management of novel drugs side effect  

Carol Moreno (Barcelona)

3. MRD assessment  

Andy Rawstron (Leeds)

**SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance**

Chair (s): TBA

08:40-08:55  

Clonal evolution  

Davide Rossi (Bellinzona)

08:55-09:00  

*Discussion*

09:00-09:15  

PI3K  

Jennifer Brown (Boston)

09:15-09:20  

*Discussion*

09:20-09:35  

Venetoclax  

John Seymour (Melbourne)

09:35-09:40  

*Discussion*

09:40-09:47  

Short talk  

TBA

09:47-09:50  

*Discussion*

09:50-10:20  

*Panel discussion*

10:20-10:50  

*Coffee break*
SESSION IX – Contrasting therapeutic concepts:
Chair(s): TBA

10:50-11:05  MRD as a dynamic endpoint  Peter Hillmen (Leeds)
11:05-11:10  Discussion

11:10-11:25  Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL  David M. Kurtz (Stanford)
11:25-11:30  Discussion

11:30-11:45  Sequential vs combination treatments  Bill Wierda (Houston)
11:45-11:50  Discussion

11:50-12:05  Time limited vs continuous treatments  Barbara Eichhorst (Cologne)
12:05-12:10  Discussion

12:10-12:40  Panel discussion

12:40-12:50  Closing Remarks

MEETING CLOSURE